Tumour suppressors: One faulty copy tips the balance | PDF (240 KB)

p725 | doi:10.1038/nrc2239

Myelodysplastic syndromes: Dia findings | PDF (122 KB)

p726 | doi:10.1038/nrc2233

Breast cancer: On the origins of tumour subtypes | PDF (364 KB)

p726 | doi:10.1038/nrc2234

Immunology: 'Danger' signals | PDF (224 KB)

p727 | doi:10.1038/nrc2240

Angiogenesis: Inside or outside? | PDF (365 KB)

p728 | doi:10.1038/nrc2235

Therapy: I look down on him... | PDF (286 KB)

p729 | doi:10.1038/nrc2237

Targeted therapy: Blast it away! | PDF (233 KB)

p730 | doi:10.1038/nrc2236

Oncogenes: Suppressive organization | PDF (202 KB)

p730 | doi:10.1038/nrc2238

Making a tumour's bed: glioblastoma stem cells and the vascular niche

Richard J. Gilbertson & Jeremy N. Rich

p733 | doi:10.1038/nrc2246

Glioblastoma stem cells might be dependent on cues from aberrant vascular niches that mimic the normal neural stem cell niche. What are the implications of these findings for treatment of this disease?

• Abstract
• Full Text
• PDF (277 KB)

Illuminating the metastatic process

Erik Sahai

p737 | doi:10.1038/nrc2229

Studying metastasis has been difficult because until recently only the end result (metastases) could be observed. Advances in imaging technology have enabled us to begin to unravel the steps of metastasis in vivo.

• Abstract
• Full Text
• PDF (1,424 KB)
• Supplementary information

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

Pedro Jares, Dolors Colomer & Elias Campo

p750 | doi:10.1038/nrc2230

Mantle cell lymphoma, characterized by proliferation of mature B lymphocytes, is one of the most aggressive lymphomas. What molecular pathways are involved in its pathogenesis, and how can these be exploited to predict patient prognosis and design new therapies?

• Abstract
• Full Text
• PDF (891 KB)

Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

Javier A. Menendez & Ruth Lupu

p763 | doi:10.1038/nrc2222

Fatty acid synthase (FASN) catalyses the synthesis of fatty acids, and this synthetic pathway is upregulated in many tumours. How might FASN and increased lipogenesis be involved in cancer, and is FASN a valid therapeutic target?

• Abstract
• Full Text
• PDF (1,350 KB)

Lung cancer in never smokers — a different disease

Sophie Sun, Joan H. Schiller & Adi F. Gazdar

p778 | doi:10.1038/nrc2190

Approximately 25% of lung cancer cases worldwide are not attributable to smoking, accounting for over 300,000 deaths each year. What do we know about this unique but poorly characterized disease?

• Abstract
• Full Text
• PDF (674 KB)